Stay updated on Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.

Latest updates to the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This is a non-functional update that does not change study content or user interactions.SummaryDifference0.0%

- Check15 days agoChange DetectedAdded Principal Investigator Julie Specht, MD and updated the recruiting contact at The Christ Hospital Cancer Center. Expanded the study locations to 15 sites, including Cincinnati, Ohio.SummaryDifference0.6%

- Check30 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is displayed across the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedGlossary show/hide controls were added and update-related labels were adjusted. Versioning information was updated to Revision: v3.4.0 and the previous Revision: v3.3.4 was removed, along with wording about No FEAR Act data.SummaryDifference0.3%

- Check58 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page. This is a minor front-end version update and does not affect study information or functionality.SummaryDifference0.0%

Stay in the know with updates to Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.